Company news
Amarantus Bioscience Holdings, Inc. news in 2018
Amarantus Bioscience Holdings, Inc.'s news releases, calls and decks from 2018, newest first.
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
December 3, 2018
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
November 28, 2018
Withdrawal of JV Offer
October 23, 2018
Term Sheet in Support of JV
October 19, 2018
Joint Venture Offer
October 18, 2018
Amarantus Provides Corporate Update
July 20, 2018
MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology
July 9, 2018
Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
May 30, 2018
Amarantus to Present at LD Micro and The Reg A Conference
May 24, 2018
Amarantus Retains Weild & Co. to Advise on JOBS Act Funding
May 22, 2018
MANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal Photoreceptor Protection Data for MANF
May 21, 2018
Amarantus Provides Business Overview
May 11, 2018
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
May 4, 2018
MANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's
May 3, 2018
Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment
May 1, 2018
Elto PharmaAppoints Paula Trzepacz, MD asChief Medical Advisor
April 30, 2018
Cutanogen Appoints Richard Kagan, MD as Chief Medical Advisor
April 23, 2018
Amarantus to Present at the Planet MicroCap Showcase 2018 in Las Vegas
April 19, 2018
Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program
April 16, 2018
Amarantus to Present at The Microcap Conference in NYC
April 9, 2018
Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test
April 6, 2018
Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor
April 5, 2018
Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City
April 2, 2018
Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City
March 28, 2018
Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia
March 8, 2018
Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
March 5, 2018
MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231
March 1, 2018
Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding
February 26, 2018
Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease
January 29, 2018
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
January 23, 2018
Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018
January 9, 2018
Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
January 4, 2018
AMBS Enters into Binding LOI to Re-acquire Rights to LymPro, MSPRecise and NuroPro
January 2, 2018
Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data
January 3, 2018